换一批
换一批Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
第一作者：
Elizabeth A,Brown
第一单位：
Bristol Myers Squibb, Princeton, NJ, USA.
作者：
关键词
ALT, alanine aminotransferaseAPRI, AST-to-platelet ratio indexAST, aspartate aminotransferaseCK-18 M30, caspase-cleaved cytokeratin 18ELF, enhanced liver fibrosisFGF21, fibroblast growth factor 21FIB-4, fibrosis-4 indexMRE, magnetic resonance elastographyMRI-PDFF, MRI-proton density fat fractionNAFLD, non-alcoholic fatty liver diseaseNAS, NAFLD activity scoreNASH, non-alcoholic steatohepatitisP3NP, procollagen-3 N-terminal propeptidePC3X, crosslinked ADAMTS-2-released N-terminal type III collagen propeptidePGBF, pegbelferminPRO-C3, monomeric ADAMTS-2-released N-terminal type III collagen propeptideSomaSignalT2D, type 2 diabetesTG, triglyceridesTIMP-1, tissue inhibitor of metalloproteinases type 1fibroblast growth factor 21liver fibrosisnon-alcoholic steatohepatitisprecirrhotic NASHsteatosis
DOI
10.1016/j.jhepr.2022.100661
PMID
36866389
发布时间
2023-03-04
- 浏览0
JHEP reports
2023年5卷4期
100661页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
